Article
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.
Future oncology (London, England) - 1 Mar 2022
Riely Gregory J, Ahn Myung-Ju, Felip Enriqueta, Ramalingam Suresh S, Smit Egbert F, Tsao Anne S, Alcasid Ann, Usari Tiziana, Wissel Paul S, Wilner Keith D, Johnson Bruce E
Abstract excerpt
BRAFV600 oncogenic driver mutations occur in 1-2% of non-small-cell lung cancers (NSCLCs) and have been shown to be a clinically relevant target. Preclinical/clinical evidence support the efficacy and safety of BRAF and MEK inhibitor combinations in patients with NSCLC with these mutations. We describe the design of PHAROS, an ongoing, open-label, single-arm, phase II trial evaluating the BRAF inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.